Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Gilbert J, Zoghbi"'
Autor:
Arie Szatkowski, Diana Barker, Amit Malhotra, Gilbert J. Zoghbi, Yaser Cheema, Brian Dragutsky, Dharmesh Patel, Darrell Sneed, Justin May, Huibo Shao
Publikováno v:
Journal of the American College of Cardiology. 73:141
Autor:
Sunil V. Rao, Walter W. Woody, Gilbert J. Zoghbi, Jennifer A. Tremmel, Tejas Patel, Christopher T. Pyne, Peter L. Duffy, Adhir Shroff, Kintur Sanghvi, Van Crisco, Ian C. Gilchrist, Samir Pancholy, Pinak B. Shah, Kimberly A. Skelding, Rajiv Gulati, Mitchell W. Krucoff
Publikováno v:
Catheterization and Cardiovascular Interventions. 83:228-236
Duke University Medical Center, Durham, North Carolina Stanford University Medical Center, Palo Alto, California Penn State Hershey Medical Center, Hershey, Pennsylvania Brigham and Women’s Hospital, Boston, Massachusetts Mayo Clinic, Rochester, Mi
Autor:
John P. Reilly, Michael J. Mack, Emmanouil S. Brilakis, Binita Shah, Gilbert J. Zoghbi, Elizabeth Holper, Lloyd W. Klein, Gregg W. Stone, Roxana Mehran, Issam Moussa
Publikováno v:
Catheterization and Cardiovascular Interventions. 83:27-36
Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention
Autor:
Binita Shah, John P. Reilly, Gregg W. Stone, Gilbert J. Zoghbi, Michael J. Mack, Elizabeth Holper, Lloyd W. Klein, Emmanouil S. Brilakis, Issam Moussa, Roxana Mehran
Publikováno v:
Journal of the American College of Cardiology. 62:1563-1570
Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention
Autor:
Ami E. Iskandrian, Gilbert J. Zoghbi
Publikováno v:
Journal of Nuclear Cardiology. 19:126-141
Selective adenosine receptor agonists have several advantages for use as stress agents in conjunction with myocardial perfusion imaging compared to the non selective agents such as adenosine and dipyridamole. This review will summarize the pre-clinic
Autor:
Vijay K. Misra, Gilbert J. Zoghbi, Silvio E. Papapietro, William B. Hillegass, Brigitta C. Brott, James C Dobbs
Publikováno v:
Vascular Health and Risk Management
Diabetics have a prothrombotic state that includes increased platelet reactivity. This contributes to the less favorable clinical outcomes observed in diabetics experiencing acute coronary syndromes as well as stable coronary artery disease. Many dia
Autor:
Ami E. Iskandrian, Gilbert J. Zoghbi
Publikováno v:
Imaging in Medicine. 2:395-406
Vasodilator stress myocardial perfusion imaging accounts for approximately half of the stress studies in the USA. Regadenoson, a selective A2A receptor agonist, was recently approved for clinical use by the US FDA. By contrast, compared with adenosin
Autor:
Fadi G. Hage, Gilbert J. Zoghbi, Rajesh Venkataraman, Gilbert J. Perry, Ami E. Iskandrian, Angelo DeMattos
Publikováno v:
Journal of the American College of Cardiology. 53:2129-2140
Chronic kidney disease (CKD) affects approximately 13% of the U.S. population and is associated with increased risk of cardiovascular complications. Once renal replacement therapy became available, it became apparent that the mode of death of patient
Publikováno v:
Echocardiography. 25:1007-1010
We present a case of 61-year-old man that was evaluated for possible aortic stenosis but did not show a left ventricular outflow gradient on invasive assessment in the catheterization laboratory. Transthoracic echocardiography showed subaortic stenos
Predictors of Survival in Patients With End-Stage Renal Disease Evaluated for Kidney Transplantation
Autor:
Ami E. Iskandrian, Fadi G. Hage, Gilbert J. Zoghbi, Raed A. Aqel, Stuart A. Smalheiser, Angelo M. de Mattos, Gilbert J. Perry, David G. Warnock, Mark H. Deierhoi
Publikováno v:
The American Journal of Cardiology. 100:1020-1025
Cardiovascular disease is the major cause of mortality in patients with end-stage renal disease (ESRD). This study examined the all-cause mortality in 3,698 patients with ESRD evaluated for kidney transplantation at our institution from 2001 to 2004.